Center for Research Translation of Systemic Exon-skipping in Muscular Dystrophy
肌营养不良症系统性外显子跳跃研究转化中心
基本信息
- 批准号:8544772
- 负责人:
- 金额:$ 146.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-09 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:Becker Muscular DystrophyBiological AssayCanis familiarisCellsClinical TrialsComplexConsensusDiagnosticDrug ApprovalDuchenne muscular dystrophyDystrophinExonsGene DeliveryGene ProteinsGenesGoalsHumanIn VitroMethodsModelingMolecularMuscleMuscular DystrophiesMutationNatural HistoryPatientsPharmaceutical PreparationsProceduresProductionProteinsRNA SplicingReadingReportingResearchSafetySystemTerminator CodonTestingTherapeuticTranscriptTranslational ResearchTranslationsViral Vectorcell bankclinical efficacycostdrug developmentexon skippingfunctional outcomesgene therapyin vivoinnovationmouse modelmutantpre-clinicalprogramsprotein functionrepairedsmall moleculestem cell therapy
项目摘要
DESCRIPTION (provided by applicant): The identification of the Duchenne muscular dystrophy gene and protein in the late 1980's led to high hopes of rapid translation to rational therapeutics. Early reports of delivering new functional genes to mouse model muscle via gene therapy and stem cell therapy fueled this hope. However, these same studies illuminated the very high hurdles facing human applications. Insufficient therapeutic material (cells, viral vectors), challenges in systemic delivery, and immunological hurdles all remain barriers to demonstration of efficacy of exogenous gene delivery. An alternative approach Is to repair the patient's own gene, and two innovative small molecule approaches have emerged as front-line experimental therapeutics: stop codon read through, and exon skipping. Both approaches are In human clinical trials, and aim to coax dystrophin protein production from mutant genes. In the clinically severe dog model of DMD, the exon-skipping approach is the first therapeutic method that showed improvement of multiple functional outcomes. The proposed CORT is focusing on exon-skipping, the approach that holds promise for the majority of DMD patients. Exon skipping as a drug development program Is highly complex. Patients have different mutations, and drugs must be customized to groups of patients sharing overlapping deletions. Given the high cost of drug development, there is an emerging consensus that exon skipping should achieve drug approval 'as a class'. Three exon-specific drugs should be systematically studied, showing safety and efficacy. The procedures and rules optimized for these three drugs can then be generalized to other, less commonly applicable exon- specific drugs, with reduced regulatory hurdles. The goal of this CORT is to systematically study the three most commonly applicable exon-specific drugs (exons 45,51.53). Project 1 will determine the splicing fidelity and protein function corresponding to the In-frame transcripts generated by the drugs. Project 2 will optimize sequence selection for each exon using multiple experimental systems, and test optimized drugs in a 1 yr pre-clinical efficacy study. Project 3 will carry out the first natural history study of the targeted in-frame deletions (Becker muscular dystrophy); this will permit some prediction of clinical efficacy from production of the relevant semi-functional dystrophin proteins. These three Projects draw upon two research cores: Core B (In vitro and In vivo functional assays), and Core C (Molecular diagnostics and cell banking).
描述(由申请人提供):20世纪80年代末,杜氏肌营养不良基因和蛋白质的鉴定使人们对快速转化为合理的治疗方法寄予厚望。通过基因治疗和干细胞治疗将新的功能基因传递给小鼠模型肌肉的早期报道助长了这一希望。然而,这些研究也说明了人类应用所面临的巨大障碍。治疗材料(细胞、病毒载体)的不足、全身递送的挑战和免疫障碍都是证明外源性基因递送有效性的障碍。另一种方法是修复患者自身的基因,两种创新的小分子方法已经成为前沿的实验治疗方法:停止密码子读取和外显子跳过。这两种方法都在人体临床试验中,旨在诱导突变基因产生肌营养不良蛋白。在临床上重度DMD犬模型中,外显子跳脱法是第一个显示多种功能预后改善的治疗方法。提议的CORT专注于外显子跳跃,这种方法对大多数DMD患者有希望。外显子跳跃作为一个药物开发项目是非常复杂的。患者有不同的突变,药物必须针对有重叠缺失的患者群体进行定制。鉴于药物开发的高成本,外显子跳跃应该“作为一类”获得药物批准,这是一个新兴的共识。三种外显子特异性药物应系统研究,显示安全性和有效性。针对这三种药物优化的程序和规则可以推广到其他不太常用的外显子特异性药物,减少了监管障碍。本CORT的目标是系统地研究三种最常用的外显子特异性药物(外显子45,51.53)。项目1将确定药物产生的帧内转录本对应的剪接保真度和蛋白质功能。项目2将使用多个实验系统优化每个外显子的序列选择,并在1年的临床前疗效研究中测试优化后的药物。项目3将对目标框内缺失(贝克肌萎缩症)进行首次自然历史研究;这将允许通过生产相关的半功能性肌营养不良蛋白来预测临床疗效。这三个项目利用了两个研究核心:核心B(体外和体内功能分析)和核心C(分子诊断和细胞库)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC P. HOFFMAN其他文献
Proteolytic fragment or new gene product?
蛋白水解片段还是新基因产物?
- DOI:
10.1038/336210a0 - 发表时间:
1988-11-01 - 期刊:
- 影响因子:48.500
- 作者:
ERIC P. HOFFMAN;LOUIS M. KUNKEL;ROBERT H. BROWN - 通讯作者:
ROBERT H. BROWN
ERIC P. HOFFMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC P. HOFFMAN', 18)}}的其他基金
Clinical Trial Readiness for Monitoring Muscle Inflammation in Duchenne Muscular Dystrophy
监测杜氏肌营养不良症肌肉炎症的临床试验准备
- 批准号:
10725465 - 财政年份:2023
- 资助金额:
$ 146.96万 - 项目类别:
Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales
商业化准备试点 (CRP),以最大限度地提高瓦莫洛龙的国际标签和销售
- 批准号:
10200153 - 财政年份:2016
- 资助金额:
$ 146.96万 - 项目类别:
K12 Career Development Program: Omics of Pediatric Lung Diseases in DC
K12 职业发展计划:华盛顿特区小儿肺部疾病组学
- 批准号:
8857246 - 财政年份:2013
- 资助金额:
$ 146.96万 - 项目类别:
K12 Career Development Program: Omics of Pediatric Lung Diseases in DC
K12 职业发展计划:华盛顿特区小儿肺部疾病组学
- 批准号:
8722615 - 财政年份:2013
- 资助金额:
$ 146.96万 - 项目类别:
K12 Career Development Program: Omics of Pediatric Lung Diseases in DC
K12 职业发展计划:华盛顿特区小儿肺部疾病组学
- 批准号:
8575197 - 财政年份:2013
- 资助金额:
$ 146.96万 - 项目类别:
Center for Research Translation of Systemic Exon-skipping in Muscular Dystrophy
肌营养不良症系统性外显子跳跃研究转化中心
- 批准号:
8330812 - 财政年份:2011
- 资助金额:
$ 146.96万 - 项目类别:
Center for Research Translation of Systemic Exon-skipping in Muscular Dystrophy
肌营养不良症系统性外显子跳跃研究转化中心
- 批准号:
8734214 - 财政年份:2011
- 资助金额:
$ 146.96万 - 项目类别:
Center for Research Translation of Systemic Exon-skipping in Muscular Dystrophy
肌营养不良症系统性外显子跳跃研究转化中心
- 批准号:
8090706 - 财政年份:2011
- 资助金额:
$ 146.96万 - 项目类别:
AN EXERCISE INTERVENTION IN INSULIN-RESISTANT MINORITY ADOLESCENTS
对胰岛素抵抗的少数青少年的运动干预
- 批准号:
8167332 - 财政年份:2010
- 资助金额:
$ 146.96万 - 项目类别:
Integrated Molecular Core for Rehabilitation Medicine
康复医学综合分子核心
- 批准号:
8053664 - 财政年份:2010
- 资助金额:
$ 146.96万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 146.96万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 146.96万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 146.96万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 146.96万 - 项目类别:
Postdoctoral Fellowships